PlGF2 Inhibitors
PlGF2 inhibitors refer to a class of chemical compounds that specifically target placental growth factor 2 (PlGF2), a key member of the vascular endothelial growth factor (VEGF) family. PlGF2 is involved in the regulation of angiogenesis, the process through which new blood vessels form from pre-existing ones. Inhibitors of PlGF2 typically function by binding to the protein itself or by interfering with its interaction with its receptors, such as VEGFR-1 (Flt-1). By disrupting these interactions, PlGF2 inhibitors can modulate endothelial cell proliferation, migration, and survival, which are essential steps in the angiogenic process. The inhibition of PlGF2 signaling affects various molecular pathways, particularly those involved in the cellular response to hypoxia, where PlGF2 is upregulated to stimulate vascular growth. The specificity of these inhibitors allows for precise modulation of angiogenic processes without broadly impacting related growth factors in the VEGF family.
Structurally, PlGF2 inhibitors can be small molecules, peptides, or even larger macromolecules like antibodies or engineered proteins. Their design often focuses on optimizing binding affinity to PlGF2 or its receptor to ensure that these inhibitors are effective even at low concentrations. Many small-molecule inhibitors are designed to mimic key portions of PlGF2 or its receptor-binding domains, acting as decoys that prevent proper receptor-ligand binding. Other strategies include inhibitors that destabilize the PlGF2 protein conformation, making it unable to interact with its target receptors. Research into the chemical synthesis of PlGF2 inhibitors has explored various scaffolds and moieties to enhance their stability, solubility, and bioavailability, aiming for maximal activity in various environments.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sulindac | 38194-50-2 | sc-202823 sc-202823A sc-202823B | 1 g 5 g 10 g | $32.00 $86.00 $150.00 | 3 | |
Sulindac may downregulate PlGF-2 expression by inhibiting cyclooxygenase enzymes, leading to a decreased production of pro-inflammatory prostaglandins that can elevate PlGF-2 levels. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin could reduce PlGF-2 expression by directly inhibiting the activation of the NF-κB transcription factor, which is responsible for initiating transcription of angiogenesis-related genes. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol may decrease PlGF-2 expression by suppressing the activation of sirtuin proteins, which can lead to the repression of genes involved in the angiogenic process. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin Gallate could inhibit PlGF-2 expression by obstructing kinase activities within signal transduction pathways that prompt the transcription of angiogenesis-promoting genes. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic Acid may decrease PlGF-2 expression by promoting cell differentiation and reducing cell proliferation rates, processes that are closely tied to the need for angiogenic factors. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 might inhibit PlGF-2 expression by blocking phosphoinositide 3-kinases, which are crucial for activating the PI3K/Akt pathway that stimulates angiogenesis-related gene expression. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 may reduce PlGF-2 levels by obstructing the activity of MEK enzymes, which are necessary for the activation of the MAPK/ERK pathway that can lead to increased angiogenic gene expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 could decrease PlGF-2 expression by inhibiting c-Jun N-terminal kinases, thereby preventing the activation of transcription factors that promote angiogenesis-related gene transcription. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone might downregulate PlGF-2 expression by triggering glucocorticoid receptors, which can suppress the activity of pro-inflammatory transcription factors that elevate PlGF-2 levels. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin could decrease PlGF-2 expression by inhibiting the mTOR pathway, which plays a critical role in cell growth and the transcription of angiogenesis-related genes. | ||||||